$221.970
-0.688 (-0.31%)Zum Schluss
STE-News
STE-Events
Steris Acquires Xodus Medical
Xodus Medical announced that it has entered into an agreement to be acquired by Steris, a global provider of products and services that support patient care with an emphasis on infection prevention. Steris is approximately $6B in revenue, with 18,000 Associates focused on providing innovative healthcare and life science products and services around the globe. "Xodus Medical's product portfolio complements and expands STERIS's offering, particularly by adding consumables used in the operating room. Its focus on products that make surgery safer aligns closely with our mission to help our Customers create a healthier and safer world," said Dan Carestio, President and Chief Executive Officer of Steris. "The business has demonstrated an ability to grow at double-digit rates with its specialty product portfolio, a steady stream of new products, and a highly effective commercial team. We look forward to welcoming the Xodus Medical team to STERIS and working together to enhance our service to our customers and value for our shareholders."
Steris Invests $600M to Build Manufacturing Center in North Carolina
Steris announced that it will be investing $600M to build a formulated chemistries manufacturing and distribution Center of Excellence in North Carolina, near the Raleigh-Durham Research Triangle region. The facility will serve as a central hub to produce high-performance infection prevention and contamination control chemistries used across the Healthcare and Pharmaceutical industries.
Steris Announces Quarterly Dividend of 69 Cents per Share
Steris announced that the company will distribute a quarterly interim dividend of 69c per share. This represents a 6c increase in the dividend. The dividend is payable on September 25 to shareholders of record at the close of business on September 4.
Company Reports Q4 Revenue of $1.6B
Reports Q4 revenue $1.6B, consensus $1.6B. "FY26 was another record year," said CEO Dan Carestio. "Our diversified Customer base and growth in procedure volumes continue to drive our performance. We appreciate the efforts of our global Associates who continue to put our Customers first. As we look ahead, we are excited for what is to come as we capitalize on our unique ability to help our Customers enable procedural growth, deliver quality outcomes and drive compliance with standardization and optimization."
Sees FY27 Revenue Growth 7%-8% from $5.9B
Sees FY27 revenue growth 7%-8% from $5.9B, consensus $6.31B. Sees FY27 CapEx $375M.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.